glp-1 receptor agonist manufacturers Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Receptor Agonists | New

The underlying mechanism of these beneficial effects has been further investigated by Ohyama et al

What Are the Negative Side Effects of GLP-1

By Lana Pine | Published on June 19, 2025 4 min read People with diabetes who take glucagon-like peptide-1 (GLP-1) receptor agonists (such as Ozempic and Wegovy) may have more than twice the risk of developing a serious eye condition called neovascular age-related macular degeneration (nAMD) a leading cause of vision loss in older adults according to a large-scale study published in JAMA Ophthalmology

SAA supervised the project

How does Zepbound compare to semaglutide for GLP-1 weight loss treatment